Leif W Ellisen
Overview
Explore the profile of Leif W Ellisen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
113
Citations
8212
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bar Y, Fell G, Dedeoglu A, Moffett N, Vidula N, Spring L, et al.
NPJ Breast Cancer
. 2025 Mar;
11(1):27.
PMID: 40069204
Trastuzumab deruxtecan (T-DXd) is approved for HER2-low (HER2 immunohistochemistry (IHC)1+ or 2+ with non-amplified in situ hybridization (ISH)), but not HER2-0 (IHC 0) metastatic breast cancer. The impact of repeat...
2.
Liu T, Ellisen L
Cancer Cell
. 2025 Mar;
43(3):332-334.
PMID: 40068590
In this issue of Cancer Cell, Zhang et al. use single-cell RNA sequencing to compare immune cell dynamics in triple-negative breast cancers treated with the PD-L1 inhibitor atezolizumab plus paclitaxel...
3.
Man K, Darweesh O, Hong J, Thompson A, OConnor C, Bonaldo C, et al.
Oncogene
. 2025 Jan;
PMID: 39890967
Triple-negative breast cancer (TNBC) is an aggressive and heterogenous breast cancer subtype. RASAL2 is a RAS GTPase-activating protein (GAP) that has been associated with platinum resistance in TNBC, but the...
4.
Spring L, Scarpetti L, Medford A, Niemierko A, Comander A, Mulvey T, et al.
NPJ Breast Cancer
. 2025 Jan;
11(1):2.
PMID: 39774684
Optimal timing and dosing of adjuvant cyclin-dependent kinase (CDK) 4/6 inhibitor in early breast cancer is controversial. This prospective phase II clinical trial investigated tolerability and safety of two ribociclib...
5.
Abelman R, Wu B, Barnes H, Medford A, Norden B, Putur A, et al.
Clin Cancer Res
. 2025 Jan;
PMID: 39745368
Purpose: Antibody-drug conjugates (ADCs) harboring topoisomerase I (TOP1) inhibitor payloads have improved survival for patients with metastatic breast cancer (MBC). However, knowledge of ADC resistance mechanisms and potential impact on...
6.
Wu B, Thant W, Bitman E, Liu T, Liu J, Paschalis E, et al.
bioRxiv
. 2024 Dec;
PMID: 39677819
Immune exclusion inhibits anti-tumor immunity and response to immunotherapy, but its mechanisms remain poorly defined. Here, we demonstrate that Trophoblast Cell-Surface Antigen 2 (TROP2), a key target of emerging anti-cancer...
7.
Wang Y, Gao B, Zhang L, Wang X, Zhu X, Yang H, et al.
Nat Commun
. 2024 May;
15(1):3819.
PMID: 38714829
No abstract available.
8.
Bardia A, Sun S, Thimmiah N, Coates J, Wu B, Abelman R, et al.
Clin Cancer Res
. 2024 May;
30(14):2917-2924.
PMID: 38709212
Purpose: The antibody-drug conjugate (ADC) sacituzumab govitecan (SG) comprises the topoisomerase 1 (TOP1) inhibitor (TOP1i) SN-38, coupled to a monoclonal antibody targeting trophoblast cell surface antigen 2 (TROP-2). Poly(ADP-ribose) polymerase...
9.
Bar Y, Keenan J, Niemierko A, Medford A, Isakoff S, Ellisen L, et al.
NPJ Breast Cancer
. 2024 Apr;
10(1):27.
PMID: 38605020
We aimed to study the incidence and genomic spectrum of actionable alterations (AA) detected in serial cfDNA collections from patients with metastatic breast cancer (MBC). Patients with MBC who underwent...
10.
Wang Y, Gao B, Zhang L, Wang X, Zhu X, Yang H, et al.
Nat Commun
. 2024 Feb;
15(1):1568.
PMID: 38383600
Drugs targeting the DNA damage response (DDR) are widely used in cancer therapy, but resistance to these drugs remains a major clinical challenge. Here, we show that SYCP2, a meiotic...